BMRN was upgraded from Hold to Buy, Roth Capital said. $23 price target. Sales of 3 existing drugs should continue to grow.

CAT was upgraded from Underweight to Overweight, Morgan Stanley said. $70 price target. Expect an increaed pace of cyclical acceleration.

EAT was upgraded from Neutral to Buy, Suntrust Robinson Humphrey said. $20 price target. Valuation call, as the company has eliminated most refinancing concerns.

FULT coverage initiated with an Overweight rating and $11 price target. Analysts noted significant slowing in the rate of credit deterioration at the commercial bank. 2010 and 2011 EPS estimates set at $0.67 and $0.93, respectively.

IR was upgraded from Underweight to Equal-weight, Morgan Stanley said. $36 price target. Seeing signs of an improvement in the HVAC and security markets.

KMX upgraded to Neutral from Underperform on belief that used car sales will be higher than new car sales, Credit Suisse said. Price target surged to $23 from $15. 2010 and 2011 EPS estimates increased to $1.15 and $1.20, respectively.

LAMR was upgraded to Outperform, Wells Fargo said. Checks show that advertising growth continues to accelerate this quarter.

MON upgraded to Buy from Neutral on attractive prospects in corn seed and a slightly more constructive outlook for Roundup, Bank of America/Merrill Lynch said. Price target goes to $96 from $94. 2010 and 2011 EPS estimates set at $3.25 and $4.30, respectively.